** Hong Kong shares of BeiGene Ltd 6160.HK jump 8.2% to HK$174.8, their highest since December 2021, and on course for fourth consecutive session of gains

** Stock on track for the biggest one-day rise since February 21

** Shanghai-listed stock 688235.SS surges 9.7% to record high at 248 yuan

** U.S. stock ONC.O jumped 7.5% on Thursday

** Chinese oncology treatments developer said its total global revenues increased 78% y/y to $1.1 bln for Q4 and it was up 55% y/y to $3.8 bln for the full year of 2024

** Full year 2025 revenue guidance of $4.9 bln to $5.3 bln - Co

** Nomura, with "Buy" rating on the stock, says 4Q24 sales beat on balanced growth in the U.S., China, EU with higher FY25E sales guided

** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both fall 1.8%, Hang Seng Index .HSI eases 1.7%

** Hong Kong-listed stock up 53.4% YTD, Shanghai shares up 50.6%, US shares up 50.7%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))